Population Pharmacokinetics and Exposure-Response for Dapirolizumab Pegol From a Phase 2b Trial in Patients With Systemic Lupus Erythematosus

Contact

Pharmetheus AB
Dag Hammarskjölds väg 36B
752 37 Uppsala, Sweden

info@pharmetheus.com
+46(0)18-51 33 28

Links

Services

About

Pharmetheus offers consulting services focused on the application of quantitative approaches to support drug development decisions..